Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]

Abstract

Niu S, Ren Q, Chen S, et al. Diabetes Metab Syndr Obes. 2023;16:2549–2560. The authors have advised the correspondence section on page 2549 is incorrect. The correct correspondence details are as follows. Correspondence: Shuchun Chen, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China, Email [email protected] The authors apologize for this error.

Keywords

• nafld
• empagliflozin
• metabolomics
• differentially expressed metabolites
• obesity